MYC and cancer: MYC, encoded by the MYC proto‐oncogene, is dysregulated in up to 70% of all human cancers through mechanisms, including genetic copy‐number gain, aberrant upstream signaling, and altered protein stability,[6] and contributes to almost every aspect of tumorigenesis.[7] To date, numerous therapeutic agents directly targeting MYC are under development; however, their clinical efficacy has yet to be established, indicating that alternative strategies for targeting MYC may need further exploration.